
France’s top generic drug maker, Biogaran, could soon be sold to a British investment fund, raising new fears about the country’s control over vital medicines.
French pharmaceutical group Servier has entered exclusive talks with BC Partners, a UK-based fund, to sell Biogaran. The deal has drawn attention from both the markets and political leaders.